HER-3 ADC

HER-3 ADC refers to a class of antibody-drug conjugates (ADCs) designed to target the Human Epidermal Growth Factor Receptor 3 (HER3/ErbB3), a member of the ErbB family of receptor tyrosine kinases that is frequently overexpressed in various solid tumors and associated with poor prognosis and therapy resistance. These ADCs consist of a humanized monoclonal antibody specific to the HER3 extracellular domain—such as mAb EV20 developed by Mediapharma—conjugated via a linker to a potent cytotoxic payload (e.g., monomethyl auristatin F or deruxtecan). The mechanism of action involves the antibody binding to HER3 on the tumor cell surface, followed by receptor-mediated endocytosis and internalization of the ADC. Once inside the lysosomal compartment, the cytotoxic payload is released, leading to cell cycle arrest and apoptosis. This approach allows for the targeted delivery of highly potent toxins while minimizing systemic toxicity. Preclinical and clinical studies have explored HER-3 ADCs in a variety of indications, including breast, lung, gastric, and pancreatic cancers, as well as melanoma.

Other names

HER3-ADCHER-3-ADCHER 3-ADCanti-HER3 ADCanti-HER-3 ADCanti-HER 3 ADCHER3 antibody-drug conjugateHER-3 antibody-drug conjugateHER 3 antibody-drug conjugate